Next Phase Newsletter

A Japanese Pharmaceutical company, with headquarters in Tokyo and offices in Japan and the US focuses on developing and marketing products in the pharmaceutical and nutraceutical businesses. Currently, the Pharma is actively seeking novel and innovative therapeutic opportunities for in-licensing in CNS and nephrology. In addition, the Pharma manages an early-stage investment fund (currently $30M) that actively invests in global early-stage opportunities that fit the firm’s areas of interest.

The Pharma is interested in innovative therapeutics that address areas of significant unmet need in CNS and renal diseases. The firm is a global leader in CNS, both neurology and psychiatry, opportunistic to all types of indications, both symptomatic and disease-modifying. In nephrology, the firm is particularly interested in novel mechanism addressing both acute and chronic kidney diseases of tubular and glomerular origin, as well as associated inflammatory and fibrotic mechanisms. The firm will consider both clinical and pre-clinical compounds with compelling biological valid proof-of-concept.

The Pharma has no specific management team requirements and will work with all types of companies with an innovative product or pipeline. The firm aims to obtain global commercial rights as a preferential end-goal.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm founded in 2015 and based in Silicon Valley makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare , including AI in healthcare and medical devices. The firm manages 3 funds right now with over $200M AUM. The firm typically invests $1M-$2M initial check per company, and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies.

The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage.

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A large Indian conglomerate headquartered in Kolkata India has many subsidiary companies, several of which are involved within the life science space. Within the hospital subsidiary, the firm is particularly interested in technologies that can help reduce costs, increase access for patient populations, process data, and keep records. The firm also runs their own incubator and is currently interested in Seed and Series A opportunities where they can put in $1-2 million USD. The firm currently prefers co-investing over leading. The firm is interested in opportunities globally, but prefers if they have an interest in working in India.

The firm is particularly interested in the digital health space, specifically telemedicine and AI-based data processing. The firm is interested in these technologies as they believe that they can leverage digital health solutions in order to reduce costs within their hospital systems as well as increase the access to patients located in remote areas. The firm is also interested in AI-based record keeping and analytic technologies as currently, medical records in India are minimal. The firm is also interested in technology related to disaster management and response. The firm is also interested in technologies that can be used to establish clinics in pharmacies as they’ve seen a trend for patients to prefer clinic visits over hospital visit in India. The firm is also particularly interested in natural remedies, specifically the use of organic and natural ingredients in Ayurveda (traditional Indian medicine). The firm also has a slight interest in genomics, but they would only be interested if a strong lead investor with genomics experience is already in place. The firm prefers investing in companies that already have proof of concept.

The firm prefers a strong management team that is dedicated and focused on seeing the project through to the end. The firm also prefers to invest alongside strong lead investors with significant experience in the field. The firm prefers to take a board seat when investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A venture capital company founded in 2005 located in Mill Valley, California is managing just under $70 million in assets across 2 funds and making equity investments into companies ranging from a few hundred thousand dollars to $2 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A diversified, global, alternative asset manager has invested equally in the private and public markets. Within the private markets, the firm seeks to invest across the entire private healthcare company lifecycle, from seed to cross-over. Initial check sizes can range from $5 – 50m and will largely depend on the stage of the company. With seed stage companies, the firm can invest $1-5m. In general, the firm ascribes to the approach of doubling the size of their prior round investment in each subsequent round (from Seed -> Series A -> Series B -> Series C -> IPO), subject to milestone achievement. The firm is currently focused on USA and Western European opportunities.

The firm’s primary investment focus is disruptive therapeutics-focused companies. The firm is most interested in genetic medicines (DNA, RNA, protein-targeted therapies including gene therapy, gene editing, oligonucleotides, and small molecule approaches), precision/targeted oncology (DNA damage repair/synthetic lethality, driver/resistance mechanisms), differentiated immunotherapies (gamma-delta T-cell-targeted, bispecific T-cell engagers, new efforts at drugging difficult checkpoints/targets), CNS disorders and autoimmune disorders (new targets of interest). The firm may consider therapeutics indications outside of CNS, oncology, and autoimmune disease on a much more selective basis. In terms of stage of development, the firm is open to pre-clinical opportunities from the lead optimization phase and beyond (discovery phase will be considered too early). The firm may consider opportunities outside of therapeutics including medical devices, diagnostics, tools and digital health, but will be much more selective.

The firm has no particular company or management team requirements. The firm is willing to lead rounds but can act as a follow-on – the firm may seek board representation when acting as the lead investor. The firm seeks to hold shares of their private company investments long after their successful IPO.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences Venture Capital firm based in USA and Canada typically makes initial investments ranging from $2-6 million of equity and looks to invest $8-12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada.

The firm invests primarily in Therapeutics and Medical Devices, with selective investments in diagnostic imaging and digital health. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with offices in USA and Europe typically makes equity investments into early-stage life science companies. The typical investment size ranges from €5-10 million. The third fund is looking to make 10 investments. The firm’s current fund is focused on the EU but the firm also invests in the US.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.